

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
12 June 2003 (12.06.2003)

PCT

(10) International Publication Number
WO 03/047646 A1

(51) International Patent Classification⁷: **A61L 27/50**,
A61K 9/00; 31/4015

(21) International Application Number: PCT/FI02/00979

(22) International Filing Date: 3 December 2002 (03.12.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/006,800 4 December 2001 (04.12.2001) US

(71) Applicant (for all designated States except US): **INION LTD** [FI/FI]; Lääkärintä 2, FIN-33520 Tampere (FI).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **PIRHONEN, Eija** [FI/FI]; Siltakatu 17 as 1, FIN-33100 Tampere (FI). **NIEUWENHUIS, Jan** [NL/NL]; Aagie Dehenstraat 6, NL-4207 KD Gorinchem (NL). **KAIKKONEN, Auvo** [FI/FI]; Ojustenkä 5 F 11, FIN-33270 Tampere (FI). **NIEMINEN, Tuomo** [FI/FI]; Sidoskuja 2 F, FIN-33820 Tampere (FI). **WEBER, Franz** [DE/DE]; Curth-Georg Beckenstr. 3, 78224 Singen (DE).

(74) Agent: **KOLSTER OY AB**; Iso Roobertinkä 23, P.O.Box 148, FIN-00121 Helsinki (FI).

(81) Designated States (national): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, ES, FI (utility model), FI, GB, GD, GE,

GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK (utility model), SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 03/047646 A1

(54) Title: RESORBABLE POLYMER COMPOSITION, IMPLANT AND METHOD OF MAKING IMPLANT

(57) Abstract: Novel polymer compositions that are useful in the manufacture of medical implants, implants having osteogenic properties and methods of making said implants are disclosed. Polymer compositions comprise a base material including a polymer matrix of resorbable polymer(s) or copolymer(s), and N-methyl-2-pyrrolidone (NMP), wherein NMP is present in an amount imparting osteogenic properties for the composition.

BEST AVAILABLE COPY

BEST AVAILABLE COPY

Resorbable polymer composition, implant and method of making implant

Field of the invention

5 **[0001]** The present invention relates to novel polymer compositions that are useful in the manufacture of medical implants. More particularly, embodiments of the invention relate to polymer compositions having osteogenic properties. The polymer compositions are biodegradable or bioresorbable and they can be fashioned into medical implants for implantation
10 in the body. Implants having osteogenic properties and methods of making said implants are also disclosed.

Background of the invention

[0002] The healing process of bone is a complicated cascade of
15 events. Rapid and diverse events are activated by a fracture or osteotomy of a bone in order to limit the loss of blood and initiate cellular migration resulting in repair. Current concepts suggest that these cellular events are controlled to a large part by growth factors, low-molecular-weight glycoproteins, inducing migration, proliferation and differentiation of an appropriate subset of cells in
20 the site of the fracture.

[0003] Despite of the amount of known details the bone healing as a whole is still a poorly understood process. Based on this lacking information and experimental data research has releaved several methods to enhance bone growth, such as mechanical stimulation, electromagnetic fields, low-
25 intensity ultrasound, osteoconductive materials, for instance hydroxyapatite, tricalcium phosphate, bioactive glass etc., and osteoinductive materials, such as growth factors.

[0004] Osteoinduction is a process where any substance, stimulation etc. starts or enhances a cellular response resulting in a bone
30 formation process. Growth factors are a wide group of molecules known to possess this effect. According to the current knowledge, bone morphogenetic proteins (BMP) are the only growth factors known to induce bone formation heterotopically by inducing undifferentiated mesenchymal cells to differentiate into osteoblasts. Consequently, several BMPs are shown to boost the bone
35 healing process when supplementary doses are given.

[0005] For example, US Patent No. 5,725,491 discloses a biodegradable film dressing as a delivery system of various therapeutic agents, such as BMPs. The therapeutic agent is delivered from the film dressing in a certain and controlled release rate. However, BMPs are produced by genetic engineering, which is still rather expensive. Also, delivery of a correct dose of BMPs is difficult and presents great challenges for the future.

[0006] Known materials, methods and implants are expensive and exploitation of such materials, methods and implants is constrained.

10 Brief description of the invention

[0007] An object of the present invention is to provide novel resorbable polymer compositions having osteogenic properties so as to alleviate the above disadvantages. Another object is to provide novel resorbable implants having osteogenic properties. A further object is to provide methods of making resorbable implants having osteogenic properties.

[0008] These objects are achieved by providing resorbable polymer compositions, resorbable implants and methods of making resorbable implants comprising a base material including a polymer matrix of resorbable polymer(s) or copolymer(s) and N-methyl-2-pyrrolidone (NMP).

[0009] According to one embodiment of the invention, the polymer matrix comprises Polylactide/Polyglycolide/Trimethylene carbonate copolymer (PLA/PGA/TMC) with a composition of 80/10/10.

[0010] According to another embodiment of the invention, the polymer matrix comprises Poly D, L-lactide/Poly L-lactide/Trimethylene carbonate copolymer (PLDLA/PLA/TMC) with a composition of 55/40/5.

[0011] According to a third embodiment of the invention, the polymer matrix comprises 80 wt-% P(L/DL)LA (70/30) and 20 wt-% PLLA/TMC (70/30).

[0012] According to a fourth embodiment of the invention, the implant is a membrane.

[0013] According to one embodiment of the method of the invention, the method comprises the steps of selecting polymer(s) or copolymer(s) of a polymer matrix of the implant, mixing said polymer(s) or copolymer(s) to form the polymer matrix, forming the implant from said polymer matrix, and adding NMP to the implant in an amount imparting osteogenic properties for said implant.

[0014] According to another embodiment of the method of the invention, the method comprises the steps of selecting polymer(s) or copolymer(s) of a polymer matrix of the implant, adding NMP to the polymer matrix in an amount imparting osteogenic properties for the implant, and
5 forming the implant from the mixture of said polymer matrix and NMP.

[0015] An advantage of polymer compositions, implants and methods of the invention is that substantially inexpensive products are achieved as compared with known solutions enhancing bone healing.

10 Brief description of the drawings

[0016] In the following the invention will be described in greater detail by means of preferred embodiments with reference to the attached drawings, in which

[0017] Figure 1a is a microscope view of a histological section of a
15 defect created in rabbit calvarial bone where said defect is covered by a (PLA/PGA/TMC) 80/10/10 membrane treated with NMP as described in example 1,

[0018] Figure 1b is a second microscope view of a histological section of a defect created in rabbit calvarial bone where said defect is covered
20 by an OsseoQuest membrane,

[0019] Figure 1c is a third microscope view of a histological section of a defect created in rabbit calvarial bone where said defect is without any membrane, and

[0020] Figure 2 is a graph showing repair of rabbit calvarial bone
25 defects.

Detailed description of the invention

[0021] The present invention relates to a combination of N-methyl-2-pyrrolidone (NMP) and resorbable polymers or copolymers. The invention is
30 based on the unexpected realization that by combining a resorbable matrix material and NMP in a certain ratio, an implant having osteogenic properties is achieved. The implant thus induces bone growth due to the osteogenic properties of the polymer composition and enhances bone healing after osteotomies and bone fractures.

[0022] The implant forms include, but are not limited to, membranes, films, plates, mesh plates, screws, taps or other formed pieces.

[0023] The implant can be prepared for example of polyglycolide, polylactides, polycaprolactones, polytrimethylenecarbonates, polyhydroxybutyrates, polyhydroxyvalerates, polydioxanones, polyorthoesters, polycarbonates, polytyrosinecarbonates, polyorthocarbonates, polyalkylene oxalates, polyalkylene succinates, poly(malic acid), poly(maleic anhydride), polypeptides, polydepsipeptides, polyvinylalcohol, polyesteramides, polyamides, polyanhydrides, polyurethanes, polyphosphazenes, polycyanoacrylates, polyfumarates, poly(amino acids), modified polysaccharides (like cellulose, starch, dextran, chitin, chitosan, etc.), modified proteins (like collagen, casein, fibrin, etc.) and their copolymers, terpolymers or combinations or mixtures or polymer blends thereof. Polyglycolide, poly(L-lactide-co-glycolide), poly(D,L-lactide-co-glycolide), poly(L-lactide), poly(D,L-lactide), poly(L-lactide-co-D,L-lactide), polycaprolactone, poly(L-lactide-co-caprolactone), poly(D,L-lactide-co-caprolactone) polytrimethylenecarbonate, poly(L-lactide-co-trimethylenecarbonate), poly(D,L-lactide-co-trimethylenecarbonate), polydioxanone and copolymers, terpolymers and polymer blends thereof are highly preferred polymers.

20

EXAMPLE 1

[0024] Polylactide/Polyglycolide/Trimethylene carbonate copolymer (PLA/PGA/TMC), with a composition of 80/10/10, granulates were compression moulded to form a film with a thickness of 0.2 mm. Used compression temperature was 180°C and pressure 130 bar. From the film 10 rectangular pieces were cut, each with a width of 20 mm.

[0025] The weight of the individual film pieces were measured with balance with an accuracy of 1 mg. The film pieces were then immersed individually into NMP for 30 seconds. After immersion the film pieces were air dried for 20 minutes and the weight of the pieces was measured again.

[0026] The weight of the film pieces before and after immersion into NMP are shown in table 1. The average amount of NMP diffused into polymeric film was 44.19 %.

35

Table 1. The weight of the film pieces before and after immersion into NMP

Weight before immersion into NMP (mg)	Weight after immersion into NMP (mg)	NMP content (mg)	Polymer content (%)	NMP content (%)
56.41	98.95	42.54	57.01	42.99
67.29	115.40	48.11	58.31	41.69
60.22	105.40	45.18	57.13	42.87
59.77	101.35	41.58	58.97	41.03
56.48	110.25	53.77	51.23	48.77
66.62	118.52	51.9	56.21	43.79
64.16	114.42	50.26	56.07	43.93
62.58	114.24	51.66	54.78	45.22
56.29	104.32	48.03	53.96	46.04
62.53	114.82	52.29	54.46	45.54

5

[0027] GTR membranes produced with the method described here in were used in a comparable rabbit study disclosed in example 2.

EXAMPLE 2

10

[0028] This rabbit study shows the osteogenetic effect of PLA/PGA/TMC and PLDLA/PLA/TMC membranes when treated with NMP. The details of the tested membranes can be found in the following table 2.

Table 2. Materials and codes of example 2

15

Code	Materials
E1M-11 NMP	PLA/PGA/TMC (80/10/10), treated with NMP (see EXAMPLE 1)
E1M-11	PLA/PGA/TMC (80/10/10)
E1M-3 NMP	PLDLA/PLA/TMC (55/40/5), treated with NMP (as in EXAMPLE 1)
E1M-3	PLDLA/PLA/TMC (55/40/5)
OsseoQuest	PLA/PGA/TMC supplier W.L.GORE & Associates, Inc.
E1M-11 with holes	PLA/PGA/TMC (80/10/10), with holes manufactured using Laser
TMC/PLA	PLA/TMC (70/30)

[0029] The study design included eight rabbits with four 6-mm artificial craniotomy defects each. The defects were treated with biodegradable membranes and a commercial biodegradable OsseoQuest membrane as shown in table 2. Controls treated without any membranes were included, too. The matrixes of the resorbable membranes are also presented in table 2.

[0030] The rabbits were sacrificed 4 weeks after the operation and the calvarial bone excised. Thorough histological analysis was performed in order to assess the degree and type of bone regeneration.

[0031] Figures 1a to 1c illustrate examples of some histological sections from the middle of the defect. It is clearly evident that the bone formed during the 4-week repair phase is more a cancellous bone than a cortical bone. A cellular interaction with the membrane was not observed.

[0032] Figure 2 shows the percentage of a full-thickness repair of rabbit calvarial bone defects. The middle sections of the defects, 6 mm in diameter in the calvarial bone were evaluated. The percentage of repair was determined by pixel number of the defect filled with bone X 100/pixel number of the defect area. The different membranes are specified by name. 'Control' means the defect without the application of a membrane.

[0033] Evaluation of the level of a full-thickness repair of the bone defect revealed that the use of membranes improved bone healing. The percentage of repair without a membrane, i.e. 'control', was $31.3 \pm 4.1\%$ of the defect area of the middle section. Essential improvement of bone healing as compared with the control was achieved with OsseoQuest ($55.78 \pm 9.9\%$), and E1M-11 NMP ($77.6 \pm 8.8\%$). A direct comparison of bone healing enhanced by OsseoQuest and E1M-11 NMP shows a clearly better healing with E1M-11 NMP. Furthermore, E1M-3NMP shows a healing effect essentially similar to OsseoQuest.

[0034] As shown in figure 2 the membranes of the present invention, i.e. E1M -3 NMP and E1M-11 NMP, increase markedly the healing response in the defect as compared with the membranes with an identical polymeric composition, i.e. E1M -3, E1M-11, that do not comprise NMP.

EXAMPLE 3

[0035] According to one embodiment of the method of the present invention, NMP is added to the polymer matrix that has been already fashioned into the form of a medical implant.

[0036] Polymer compositions were prepared by dry-mixing commercially available granular-form base materials with commercially available copolymer additives. The material composition was 80 wt-% P(L/DL)LA (70/30) and 20 wt-% PLLA/TMC (70/30). The components were weighed according to a desired weight ratio into a container which was then rotated in a Turbula T2F shaker mixer for 30 minutes until a homogenous dry mixture was obtained. The resulting mixture was then dried in vacuum at 60°C for 8 to 12 hours and thereafter melt-blended and injection-moulded in to plate-shaped test pieces. The injection-moulding machine used was a fully electric Fanuc Roboshot Alpha i30A injection-moulding machine with a mould clamping force of 300 kN. The injection unit was equipped with high speed (max. 66 cm³/s to 330 mm/s), high pressure (max. 2500 bar) injection options. The barrel diameter was 16 mm and it was equipped with three-band heater zones, a standard profile anticorrosion screw and a standard open nozzle with a 2.5 mm hole. The extruder melt-blending and homogenization conditions of the material during the metering phase of the process included a back pressure of 40 to 60 bar, a screw speed of 60 to 100 rpm and barrel temperatures of 160 to 230°C. Injection moulding conditions included a nozzle temperature of 180 to 230°C, an injection speed of 80 to 300 mm/s, a maximum injection pressure of 2500 bar, a pack pressure of 1000 to 2300 bar for 3 to 8 s, a cooling time of 10 to 22 s and a mould temperature of 20 to 30°C. The total cycle time was 20 to 40 s consisting of the following phases during one injection-moulding process cycle: closing of the mould, injection of the molten polymer into the mould, pack pressure, cooling while extruder was metering for the next cycle during cooling phase, opening the mould and ejection of article from the mould.

[0037] The plates were sterilized by gamma irradiation with a nominal dose of 25 kGy. After sterilisation, the plates were submerged in NMP (1-Methyl-2-pyrrolidinone, 99%, Acros Organics, Inc., USA) for 30 seconds. After submerging the plates were set for 30 minutes on a plastic holder at room conditions at 20°C. Thickness, length and mass of the plates were measured before submerging and 30 minutes thereafter. Dimensions were measured with a slide gauge and mass with an analysis balance. Additionally, 30, 60 and 120 minutes after the submerging of the plate, it was bent to 45° angle to find out softening and bending characteristics of the plate. The diffusion depth of the NMP was analysed with SmartScope Flash optical 3D-measuring device. Approximately 1 mm of the material was cut off from the edge of the plate. The

depth of the diffusion was measured from the cut cross-section of the plate 120 minutes after submerging. The results of the NMP diffusion after 30 min of submerging are shown in table 3.

5 **Table 3.** Mass and dimensions of the plate before and after submerging in the NMP

	Mass of the plate (mg)	Mass of the NMP in the plate (mg)	Thickness (mm)	Thickness of the outer layer (mm)	Length (mm)
Initial	470.8	-	1.01	0	23.5
30 min after submerging	575.7	104.9	1.15	0.15	23.6

10 [0038] The thickness of the plate was increased 13% and its mass was increased 22 % due to the submerging of the plate in NMP. The increase of the mass can be seen as the diffusion of NMP into the plate. The increase of the thickness is due to the swelling of the outer layer of the plate. The thickness of the swollen outer layer of the plate was ca. 0.15 mm. The length was not changed due to the submerging. Moreover, 30 minutes after
 15 submerging the plate was softened and bendable by hand.

[0039] Resorbable polymer matrix absorbs NMP when immersed into it. Thereafter, an implant loaded with NMP is implanted into the body, and NMP is released gradually during a certain period of time. If the rate of releasing is appropriate, NMP owns osteogenic properties. As with almost any
 20 pharmaceuticals, the concentration of NMP must be within certain limits, called a therapeutic window. Below the window, NMP is inefficacious. Correspondingly, above the window, NMP presents an adverse event by inhibiting certain proteins, other molecules or cell lines. The NMP content is preferably between 0.05 and 50 weight- %, more preferably between 0.1 and
 25 10 weight-%.

[0040] According to one preferred embodiment of the method of the present invention, NMP is mixed with a polymer matrix or one of its components before the polymer matrix is fashioned into the form of a medical implant. The mixing can take place in an extruder, in a mixer or similar

equipment known per se.

[0041] NMP may be applied to the implant as well by packing said implant into a container with NMP already in the production process. NMP will be absorbed to the polymer matrix of the implant during storage in said
5 container.

[0042] The polymer composition of the present invention can be fashioned into implants by injection moulding, compression moulding, extrusion or with another melt-moulding process known by persons skilled in the art.
10

EXAMPLE 4

[0043] Example 4 presents one preferred embodiment of the present invention, where the implant is a barrier membrane in Guided Tissue Regeneration (GTR) to treat a periodontal defect.

15 [0044] The membrane comprises PLA/PGA-matrix polymers. The membrane is packaged in a slot of a package, such as a plastic blister. The preparation of the membrane is conducted as one stage of surgical operation as follows:

[0045] 1. After opening the package, a proper amount of NMP is
20 poured into the membrane slot. The membrane is fully immersed in NMP for an adequate period, for example 30 seconds to 3 minutes, preferably for 30 seconds.

[0046] 2. The membrane is removed from the slot.

[0047] 3. NMP is allowed to diffuse into the polymer matrix of the
25 membrane for 15 to 20 minutes.

[0048] 4. The membrane is ready for use as a barrier between the gingival soft tissue and the healing bone tissue and/or periodontal tissues in order to prevent the gingival soft tissue filling the defect side. In the conditions of a normal operating theater temperature and humidity, the membrane stays
30 malleable for several hours.

[0049] Implants of the invention can be used for example in guided bone regeneration applications, where the effect of a NMP loaded barrier membrane is required to avoid soft tissue ingrowth in the area where new bone formation is required, and to enhance bone regeneration.

35 [0050] It will be obvious to a person skilled in the art that, as the technology advances, the inventive concept can be implemented in various

ways. The invention and its embodiments are not limited to the examples described above but may vary within the scope of the claims.

Claims

1. A resorbable polymer composition comprising:
a base material including a polymer matrix of resorbable polymer or copolymer, and
5 N-methyl-2-pyrrolidone (NMP),
wherein NMP is present in an amount imparting osteogenic properties for the composition.
2. The resorbable polymer composition of claim 1, wherein the
10 polymer matrix is selected from a group consisting of polyglycolide, polylactides, polycaprolactones, polytrimethylenecarbonates, polyhydroxybutyrates, polyhydroxyvalerates, polydioxanones, polyorthoesters, polycarbonates, polytyrosinecarbonates, polyorthocarbonates, polyalkylene oxalates, polyalkylene succinates, poly(malic acid), poly(maleic anhydride),
15 polypeptides, polydepsipeptides, polyvinylalcohol, polyesteramides, polyamides, polyanhydrides, polyurethanes, polyphosphazenes, polycyanoacrylates, polyfumarates, poly(amino acids), modified polysaccharides, modified proteins and their copolymers, terpolymers or combinations or mixtures or polymer blends thereof.
- 20 3. The resorbable polymer composition of claim 1, wherein the polymer matrix is selected from the group consisting of polyglycolide, poly(L-lactide-co-glycolide), poly(D,L-lactide-co-glycolide), poly(L-lactide), poly(D,L-lactide), poly(L-lactide-co-D,L-lactide), polycaprolactone, poly(L-lactide-co-caprolactone),
25 poly(D,L-lactide-co-caprolactone) polytrimethylenecarbonate, poly(L-lactide-co-trimethylenecarbonate), poly(D,L-lactide-co-trimethylenecarbonate), polydioxanone and their copolymers, terpolymers or combinations or mixtures or polymer blends thereof.
- 30 4. The resorbable polymer composition of claim 1, wherein NMP is present in an amount between 0.05 and 50 weight- %.
5. A resorbable implant having osteogenic properties, comprising:
a base material including polymer matrix of resorbable polymer or
35 copolymer, and
N-methyl-2-pyrrolidone (NMP).

6. The resorbable implant of claim 5, wherein the polymer matrix is selected from a group consisting of polyglycolide, polylactides, polycaprolactones, polytrimethylenecarbonates, polyhydroxybutyrates, polyhydroxyvalerates, polydioxanones, polyorthoesters, polycarbonates, polytyrosinecarbonates, polyorthocarbonates, polyalkylene oxalates, polyalkylene succinates, poly(malic acid), poly(maleic anhydride), polypeptides, polydepsipeptides, polyvinylalcohol, polyesteramides, polyamides, polyanhydrides, polyurethanes, polyphosphazenes, polycyanoacrylates, polyfumarates, poly(amino acids), modified polysaccharides, modified proteins and their copolymers, terpolymers or combinations or mixtures or polymer blends thereof.

7. The resorbable implant of claim 5, wherein the polymer matrix is selected from a group consisting of polyglycolide, poly(L-lactide-co-glycolide), poly(D,L-lactide-co-glycolide), poly(L-lactide), poly(D,L-lactide), poly(L-lactide-co-D,L-lactide), polycaprolactone, poly(L-lactide-co-caprolactone), poly(D,L-lactide-co-caprolactone) polytrimethylenecarbonate, poly(L-lactide-co-trimethylenecarbonate), poly(D,L-lactide-co-trimethylenecarbonate), polydioxanone and their copolymers, terpolymers or combinations or mixtures or polymer blends thereof.

8. The resorbable implant having osteogenic properties of claim 5, wherein NMP is present in an amount between 0.05 and 50 weight- %.

9. A method of making an implant having osteogenic properties comprising the steps of:

selecting polymer(s) or copolymer(s) of a polymer matrix of the implant,
adding NMP to the polymer matrix in an amount imparting osteogenic properties for the implant,
forming the implant from the mixture of said polymer matrix and NMP.

10. A method of making an implant having osteogenic properties comprising the steps of:

selecting polymer(s) or copolymer(s) of a polymer matrix of the
implant,

mixing said polymer(s) or copolymer(s) to form the polymer matrix,
forming the implant from said polymer matrix,

5 adding NMP to the implant in an amount imparting osteogenic
properties for said implant.

11. The method of *making an implant having osteogenic properties*
of claim 10, wherein NMP is added to the implant preoperatively.

1/1




Fig. 1a

Fig. 1b

Fig. 1c




Fig. 2

INTERNATIONAL SEARCH REPORT

International application No.

PCT/FI 02/00979

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: A61C 27/50, A61K 9/00, A61K 31/4015

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: A61L, A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-INTERNAL, WPI DATA, PAJ, CHEM.ABS.DATA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6245345 B1 (DERYL D. SWANBOM ET AL), 12 June 2001 (12.06.01), column 6, line 16 - line 26, abstract, examples, claims --	1-11
X	US 6261583 B1 (RICHARD L. DUNN ET AL), 17 July 2001 (17.07.01), abstract, claims --	1-11
X	US 5725491 A (ARTHUR J. TIPTON ET AL), 10 March 1998 (10.03.98), abstract --	1-11
X	WO 0200137 A1 (SHUKLA, ATUL, J.), 3 January 2002 (03.01.02), abstract, claims --	1-11

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

20 March 2003

Date of mailing of the international search report

21-03-2003

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer

Monika Bohlin/Els
Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/FI 02/00979

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 9639134 A1 (TAKEDA CHEMICAL INDUSTRIES, LTD.), 12 December 1996 (12.12.96), abstract, claims --	1-11
A	US 5378472 A (RICARDO MUZZARELLI), 3 January 1995 (03.01.95), abstract, claims --	1-11
A	Biomaterials, volyme 14, no. 1, 1993, R.A.A. Muzzarelli et al: "Osteoconduction exerted by methylpyrrolidinone chitosan used in dental surgery", pages 39-43 -- -----	1-11

INTERNATIONAL SEARCH REPORT

Information on patent family members

30/12/02

International application No.

PCT/FI 02/00979

Patent document cited in search report				Publication date		Patent family member(s)	Publication date
US	6245345	B1	12/06/01	AT	224927	T	15/10/02
				AU	746174	B	18/04/02
				AU	746269	B	18/04/02
				AU	2829299	A	09/08/99
				AU	4858299	A	24/01/00
				BR	9907733	A	17/10/00
				CA	2318639	A	29/07/99
				CA	2336900	A	13/01/00
				CN	1294576	T	09/05/01
				DE	69903168	D	00/00/00
				EE	200000428	A	17/12/01
				EP	1049665	A	08/11/00
				EP	1095096	A,B	02/05/01
				SE	1095096	T3	
				HU	0100336	A	30/07/01
				IL	137329	D	00/00/00
				JP	2002501039	T	15/01/02
				JP	2002519494	T	02/07/02
				NO	20003694	A	20/09/00
				PL	341899	A	07/05/01
				US	6407065	B	18/06/02
				US	6432923	B	13/08/02
				US	2001033853	A	25/10/01
				WO	0001760	A	13/01/00
				WO	9937605	A	29/07/99
US	6261583	B1	17/07/01	AU	4979499	A	21/02/00
				CA	2338605	A	10/02/00
				EP	1100460	A	23/05/01
				JP	2002537221	T	05/11/02
				WO	0006117	A	10/02/00

INTERNATIONAL SEARCH REPORT

Information on patent family members

30/12/02

International application No.

PCT/FI 02/00979

Patent document cited in search report			Publication date	Patent family member(s)	Publication date
US	5725491	A	10/03/98	US 5632727 A	27/05/97
				US 5792469 A	11/08/98
				AU 3117493 A	16/09/93
				CA 2091552 A	13/09/93
				EP 0560014 A	15/09/93
				JP 6007423 A	18/01/94
				US RE37950 E	31/12/02
				US 5340849 A	23/08/94
				US 5733950 A	31/03/98
				US 5739176 A	14/04/98
				US 5990194 A	23/11/99
				US 5278201 A	11/01/94
				US 5278202 A	11/01/94
				AT 151257 T	15/04/97
				AT 228861 T	15/12/02
				AU 644581 B	16/12/93
				AU 666050 B	25/01/96
				AU 4501789 A	01/05/90
				AU 5067793 A	17/02/94
				BR 8907686 A	30/07/91
				DE 68927956 D,T	17/07/97
				DE 68929441 D	00/00/00
				DK 57291 A	03/06/91
				EP 0436667 A,B	17/07/91
				SE 0436667 T3	
				EP 0773034 A,B	14/05/97
				HK 1005012 A	00/00/00
				IL 91850 A	30/03/95
				IL 107393 A	29/06/95
				JP 2992046 B	20/12/99
				JP 4503163 T	11/06/92
				KR 158669 B	15/12/98
				KR 158670 B	15/12/98
				NO 304413 B	14/12/98
				NO 911277 A	31/05/91
				US 4938763 A,B	03/07/90
				WO 9003768 A	19/04/90
				ZA 8907511 A	26/06/91
WO	0200137	A1	03/01/02	AU 4534601 A	08/01/02
				CN 1332016 A	23/01/02
				US 6432438 B	13/08/02

INTERNATIONAL SEARCH REPORT

Information on patent family members

30/12/02

International application No.

PCT/FI 02/00979

Patent document cited in search report			Publication date	Patent family member(s)		Publication date
WO	9639134	A1	12/12/96	AU	717260 B	23/03/00
				AU	5845796 A	24/12/96
				CA	2221784 A	12/12/96
				EP	0831808 A	01/04/98
				HU	9802573 A	28/09/99
				JP	2992677 B	20/12/99
				JP	9263545 A	07/10/97
				NO	975636 A	28/01/98
				NZ	308658 A	28/10/99
				RU	2188011 C	27/08/02
				TW	420608 B	00/00/00
				US	5910492 A	08/06/99
				BR	9602633 A	22/04/98
US	5378472	A	03/01/95	CZ	9202305 A	17/02/93
				DE	69118683 D,T	29/08/96
				EP	0512095 A,B	11/11/92
				SE	0512095 T3	
				AT	136553 T	15/04/96
				AU	639163 B	15/07/93
				AU	8956691 A	25/06/92
				CA	2074517 A	27/05/92
				CZ	281052 B	12/06/96
				ES	2084838 T	16/05/96
				HU	62017 A	29/03/93
				HU	9202434 D	00/00/00
				IT	64290 D	00/00/00
				IT	1243260 B	26/05/94
				JP	5503733 T	17/06/93
				WO	9209635 A	11/06/92

REVISED VERSION

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
12 June 2003 (12.06.2003)

PCT

(10) International Publication Number
WO 2003/047646 A1

(51) International Patent Classification⁷: A61L 27/50,
A61K 9/00, 31/4015

(21) International Application Number:
PCT/FI2002/000979

(22) International Filing Date: 3 December 2002 (03.12.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/006,800 4 December 2001 (04.12.2001) US

(71) Applicant (for all designated States except US): INION
LTD [FI/FI]; Lääkärinkatu 2, FIN-33520 Tampere (FI).

(72) Inventors; and

(75) Inventors/Applicants (for US only): PIRHONEN, Eija
[FI/FI]; Siltakatu 17 as 1, FIN-33100 Tampere (FI).
NIEUWENHUIS, Jan [NL/NL]; Aagie Dehenstraat 6,
NL-4207 KD Gorinchem (NL). KAIKKONEN, Auvo
[FI/FI]; Ojustenkatu 5 F 11, FIN-33270 Tampere (FI).
NIEMINEN, Tuomo [FI/FI]; Sidoskuja 2 F, FIN-33820
Tampere (FI). WEBER, Franz [DE/DE]; Curth-Georg
Beckenstr. 3, 78224 Singen (DE).

(74) Agent: KOLSTER OY AB; Iso Roobertinkatu 23,
P.O.Box 148, FIN-00121 Helsinki (FI).

(81) Designated States (national): AE, AG, AL, AM, AT (util-
ity model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,
CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (util-
ity model), DE, DK (utility model), DK, DM, DZ, EC, EE
(utility model), EE, ES, FI (utility model), FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,
MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK (utility model), SK, SL, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii)) for the following designations AE,
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG,
KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,
MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ,
VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS,
MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent
(AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB,
GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG)

Published:

— with international search report

(88) Date of publication of the revised international search
report: 29 January 2004

Date of publication of the revised international search
report: 27 May 2004

(15) Information about Corrections:

see PCT Gazette No. 22/2004 of 27 May 2004, Section II

Previous Correction:

see PCT Gazette No. 05/2004 of 29 January 2004, Sec-
tion II

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: RESORBABLE POLYMER COMPOSITION, IMPLANT AND METHOD OF MAKING IMPLANT

(57) Abstract: Novel polymer compositions that are useful in the manufacture of medical implants, implants having osteogenic properties and methods of making said implants are disclosed. Polymer compositions comprise a base material including a poly-
mer matrix of resorbable polymer(s) or copolymer(s), and N-methyl-2-pyrrolidone (NMP), wherein NMP is present in an amount
imparting osteogenic properties for the composition.

WO 2003/047646 A1

INTERNATIONAL SEARCH REPORT

International application No.

PCT/FI 02/00979

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: A61L 27/50, A61K 9/00, A61K 31/4015
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: A61L, A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-INTERNAL, WPI DATA, PAJ, CHEM.ABS.DATA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6245345 B1 (DERYL D. SWANBOM ET AL), 12 June 2001 (12.06.01), column 6, line 16 - line 26, abstract, examples, claims --	1-11
X	US 6261583 B1 (RICHARD L. DUNN ET AL), 17 July 2001 (17.07.01), abstract, claims --	1-11
X	US 5725491 A (ARTHUR J. TIPTON ET AL), 10 March 1998 (10.03.98), abstract --	1-4
X	WO 0200137 A1 (SHUKLA, ATUL, J.), 3 January 2002 (03.01.02), abstract, claims --	1-11

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

20 March 2003

Date of mailing of the international search report

12-11-2003

Name and mailing address of the ISA/

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

Monika Bohlin/Els

Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/FI 2002/000979

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 9639134 A1 (TAKEDA CHEMICAL INDUSTRIES, LTD.), 12 December 1996 (12.12.1996); abstract, claims --	1-11
A	US 5378472 A (RICARDO MUZZARELLI), 3 January 1995 (03.01.1995), abstract, claims --	1-11
A	Biomaterials, volyme 14, no. 1, 1993, R.A.A. Muzzarelli et al: "Osteoconduction exerted by methylpyrrolidinone chitosan used in dental surgery", pages 39-43 --	1-11
X	US 5077049 A (RICHARD L. DUNN ET AL), 31 December 1991 (31.12.1991), column 2, line 38 - line 57; column 4, line 5 - line 7, claims 1 and 4, abstract -- -----	1-11

INTERNATIONAL SEARCH REPORT

Information on patent family members

30/12/02

International application No.

PCT/FI 02/00979

Patent document cited in search report			Publication date	Patent family member(s)	Publication date	
US	6245345	B1	12/06/01	AT	224927 T	15/10/02
				AU	746174 B	18/04/02
				AU	746269 B	18/04/02
				AU	2829299 A	09/08/99
				AU	4858299 A	24/01/00
				BR	9907733 A	17/10/00
				CA	2318639 A	29/07/99
				CA	2336900 A	13/01/00
				CN	1294576 T	09/05/01
				DE	69903168 D	00/00/00
				EE	200000428 A	17/12/01
				EP	1049665 A	08/11/00
				EP	1095096 A,B	02/05/01
				SE	1095096 T3	
				HU	0100336 A	30/07/01
				IL	137329 D	00/00/00
				JP	2002501039 T	15/01/02
				JP	2002519494 T	02/07/02
				NO	20003694 A	20/09/00
				PL	341899 A	07/05/01
				US	6407065 B	18/06/02
				US	6432923 B	13/08/02
				US	2001033853 A	25/10/01
				WO	0001760 A	13/01/00
				WO	9937605 A	29/07/99
US	6261583	B1	17/07/01	AU	4979499 A	21/02/00
				CA	2338605 A	10/02/00
				EP	1100460 A	23/05/01
				JP	2002537221 T	05/11/02
				WO	0006117 A	10/02/00

INTERNATIONAL SEARCH REPORT

Information on patent family members

30/12/02

International application No.

PCT/FI 02/00979

Patent document cited in search report			Publication date	Patent family member(s)	Publication date
US	5725491	A	10/03/98	US 5632727 A	27/05/97
				US 5792469 A	11/08/98
				AU 3117493 A	16/09/93
				CA 2091552 A	13/09/93
				EP 0560014 A	15/09/93
				JP 6007423 A	18/01/94
				US RE37950 E	31/12/02
				US 5340849 A	23/08/94
				US 5733950 A	31/03/98
				US 5739176 A	14/04/98
				US 5990194 A	23/11/99
				US 5278201 A	11/01/94
				US 5278202 A	11/01/94
				AT 151257 T	15/04/97
				AT 228861 T	15/12/02
				AU 644581 B	16/12/93
				AU 666050 B	25/01/96
				AU 4501789 A	01/05/90
				AU 5067793 A	17/02/94
				BR 8907686 A	30/07/91
				DE 68927956 D,T	17/07/97
				DE 68929441 D	00/00/00
				DK 57291 A	03/06/91
				EP 0436667 A,B	17/07/91
				SE 0436667 T3	
				EP 0773034 A,B	14/05/97
				HK 1005012 A	00/00/00
				IL 91850 A	30/03/95
				IL 107393 A	29/06/95
				JP 2992046 B	20/12/99
				JP 4503163 T	11/06/92
				KR 158669 B	15/12/98
				KR 158670 B	15/12/98
				NO 304413 B	14/12/98
				NO 911277 A	31/05/91
				US 4938763 A,B	03/07/90
				WO 9003768 A	19/04/90
				ZA 8907511 A	26/06/91
WO	0200137	A1	03/01/02	AU 4534601 A	08/01/02
				CN 1332016 A	23/01/02
				US 6432438 B	13/08/02

INTERNATIONAL SEARCH REPORT

Information on patent family members

30/12/02

International application No.

PCT/FI 02/00979

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9639134 A1	12/12/96	AU 717260 B	23/03/00
		AU 5845796 A	24/12/96
		CA 2221784 A	12/12/96
		EP 0831808 A	01/04/98
		HU 9802573 A	28/09/99
		JP 2992677 B	20/12/99
		JP 9263545 A	07/10/97
		NO 975636 A	28/01/98
		NZ 308658 A	28/10/99
		RU 2188011 C	27/08/02
		TW 420608 B	00/00/00
		US 5910492 A	08/06/99
		BR 9602633 A	22/04/98
US 5378472 A	03/01/95	CZ 9202305 A	17/02/93
		DE 69118683 D,T	29/08/96
		EP 0512095 A,B	11/11/92
		SE 0512095 T3	
		AT 136553 T	15/04/96
		AU 639163 B	15/07/93
		AU 8956691 A	25/06/92
		CA 2074517 A	27/05/92
		CZ 281052 B	12/06/96
		ES 2084838 T	16/05/96
		HU 62017 A	29/03/93
		HU 9202434 D	00/00/00
		IT 64290 D	00/00/00
		IT 1243260 B	26/05/94
		JP 5503733 T	17/06/93
		WO 9209635 A	11/06/92

INTERNATIONAL SEARCH REPORT

Information on patent family members.

24/12/2003

International application No.

PCT/FI 2002/000979

US	5077049	A	31/12/1991	AT	100308	T	15/02/1994
				AU	653498	B	06/10/1994
				AU	6071890	A	22/02/1991
				CA	2063729	A,C	25/01/1991
				DE	69006216	D,T	05/05/1994
				DK	484387	T	14/03/1994
				EP	0484387	A,B	13/05/1992
				SE	0484387	T3	
				ES	2062540	T	16/12/1994
				FI	920293	D	00/00/0000
				HK	1005426	A	00/00/0000
				JP	2685353	B	03/12/1997
				JP	5504941	T	29/07/1993
				NO	920302	A	24/01/1992
				US	5324519	A	28/06/1994
				US	5368859	A	29/11/1994
				US	5487897	A	30/01/1996
				US	5599552	A	04/02/1997
				US	5660849	A	26/08/1997
				US	6071530	A	06/06/2000
				US	6395293	B	28/05/2002
				US	2002001608	A	03/01/2002
				WO	9101126	A	07/02/1991

REVISED VERSION

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
12 June 2003 (12.06.2003)

PCT

(10) International Publication Number
WO 2003/047646 A1

(51) International Patent Classification⁷: A61L 27/50,
A61K 9/00, 31/4015

(21) International Application Number:
PCT/FI2002/000979

(22) International Filing Date: 3 December 2002 (03.12.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/006,800 4 December 2001 (04.12.2001) US

(71) Applicant (for all designated States except US): INION
LTD [FI/FI]; Lääkärinkatu 2, FIN-33520 Tampere (FI).

(72) Inventors; and

(75) Inventors/Applicants (for US only): PIRHONEN, Eija
[FI/FI]; Siltakatu 17 as 1, FIN-33100 Tampere (FI).
NIEUWENHUIS, Jan [NL/NL]; Aagie Dehenstraat 6,
NL-4207 KD Gorinchem (NL). KAIKKONEN, Auvo
[FI/FI]; Ojustenkatu 5 F 11, FIN-33270 Tampere (FI).
NIEMINEN, Tuomo [FI/FI]; Sidokujja 2 F, FIN-33820
Tampere (FI). WEBER, Franz [DE/DE]; Curth-Georg
Beckenstr. 3, 78224 Singen (DE).

(74) Agent: KOLSTER OY AB; Iso Roobertinkatu 23,
P.O.Box 148, FIN-00121 Helsinki (FI).

(81) Designated States (national): AE, AG, AL, AM, AT (uti-
lity model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA,
CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (uti-
lity model), DE, DK (utility model), DK, DM, DZ, EC, EE
(utility model), EE, ES, FI (utility model), FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,
MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK (utility model), SK, SL, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii)) for the following designations AE,
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG,
KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,
MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ,
VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS,
MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent
(AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB,
GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG)

Published:

— with international search report

(88) Date of publication of the revised international search
report: 29 January 2004

Date of publication of the revised international search
report: 27 May 2004

(15) Information about Corrections:

see PCT Gazette No. 22/2004 of 27 May 2004, Section II

Previous Correction:

see PCT Gazette No. 05/2004 of 29 January 2004, Sec-
tion II

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: RESORBABLE POLYMER COMPOSITION, IMPLANT AND METHOD OF MAKING IMPLANT

(57) Abstract: Novel polymer compositions that are useful in the manufacture of medical implants, implants having osteogenic properties and methods of making said implants are disclosed. Polymer compositions comprise a base material including a poly-
mer matrix of resorbable polymer(s) or copolymer(s), and N-methyl-2-pyrrolidone (NMP), wherein NMP is present in an amount
imparting osteogenic properties for the composition.

WO 2003/047646 A1

INTERNATIONAL SEARCH REPORT

International application No.

PCT/FI 02/00979

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: A61L 27/50, A61K 9/00, A61K 31/4015

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: A61L, A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-INTERNAL, WPI DATA, PAJ, CHEM.ABS.DATA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6245345 B1 (DERYL D. SWANBOM ET AL), 12 June 2001 (12.06.01), column 6, line 16 - line 26, abstract, examples, claims --	1-11
X	US 6261583 B1 (RICHARD L. DUNN ET AL), 17 July 2001 (17.07.01), abstract, claims --	1-11
X	US 5725491 A (ARTHUR J. TIPTON ET AL), 10 March 1998 (10.03.98), abstract --	1-4
X	WO 0200137 A1 (SHUKLA, ATUL, J.), 3 January 2002 (03.01.02), abstract, claims --	1-11

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

20 March 2003

Date of mailing of the international search report

12-11-2003

Name and mailing address of the ISA/

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

Monika Bohlin/Els

Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/FI 2002/000979

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 9639134 A1 (TAKEDA CHEMICAL INDUSTRIES, LTD.), 12 December 1996 (12.12.1996); abstract, claims --	1-11
A	US 5378472 A (RICARDO MUZZARELLI), 3 January 1995 (03.01.1995), abstract, claims --	1-11
A	Biomaterials, volume 14, no. 1, 1993, R.A.A. Muzzarelli et al: "Osteoconduction exerted by methylpyrrolidinone chitosan used in dental surgery", pages 39-43 --	1-11
X	US 5077049 A (RICHARD L. DUNN ET AL), 31 December 1991 (31.12.1991), column 2, line 38 - line 57; column 4, line 5 - line 7, claims 1 and 4, abstract -----	1-11

INTERNATIONAL SEARCH REPORT

Information on patent family members

30/12/02

International application No.

PCT/FI 02/00979

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 6245345 B1	12/06/01	AT 224927 T	15/10/02
		AU 746174 B	18/04/02
		AU 746269 B	18/04/02
		AU 2829299 A	09/08/99
		AU 4858299 A	24/01/00
		BR 9907733 A	17/10/00
		CA 2318639 A	29/07/99
		CA 2336900 A	13/01/00
		CN 1294576 T	09/05/01
		DE 69903168 D	00/00/00
		EE 200000428 A	17/12/01
		EP 1049665 A	08/11/00
		EP 1095096 A,B	02/05/01
		SE 1095096 T3	
		HU 0100336 A	30/07/01
		IL 137329 D	00/00/00
		JP 2002501039 T	15/01/02
		JP 2002519494 T	02/07/02
		NO 20003694 A	20/09/00
		PL 341899 A	07/05/01
		US 6407065 B	18/06/02
		US 6432923 B	13/08/02
		US 2001033853 A	25/10/01
		WO 0001760 A	13/01/00
		WO 9937605 A	29/07/99
US 6261583 B1	17/07/01	AU 4979499 A	21/02/00
		CA 2338605 A	10/02/00
		EP 1100460 A	23/05/01
		JP 2002537221 T	05/11/02
		WO 0006117 A	10/02/00

INTERNATIONAL SEARCH REPORT

Information on patent family members

30/12/02

International application No.

PCT/FI 02/00979

Patent document cited in search report			Publication date	Patent family member(s)	Publication date
US	5725491	A	10/03/98	US 5632727 A	27/05/97
				US 5792469 A	11/08/98
				AU 3117493 A	16/09/93
				CA 2091552 A	13/09/93
				EP 0560014 A	15/09/93
				JP 6007423 A	18/01/94
				US RE37950 E	31/12/02
				US 5340849 A	23/08/94
				US 5733950 A	31/03/98
				US 5739176 A	14/04/98
				US 5990194 A	23/11/99
				US 5278201 A	11/01/94
				US 5278202 A	11/01/94
				AT 151257 T	15/04/97
				AT 228861 T	15/12/02
				AU 644581 B	16/12/93
				AU 666050 B	25/01/96
				AU 4501789 A	01/05/90
				AU 5067793 A	17/02/94
				BR 8907686 A	30/07/91
				DE 68927956 D,T	17/07/97
				DE 68929441 D	00/00/00
				DK 57291 A	03/06/91
				EP 0436667 A,B	17/07/91
				SE 0436667 T3	
				EP 0773034 A,B	14/05/97
				HK 1005012 A	00/00/00
				IL 91850 A	30/03/95
				IL 107393 A	29/06/95
				JP 2992046 B	20/12/99
				JP 4503163 T	11/06/92
				KR 158669 B	15/12/98
				KR 158670 B	15/12/98
				NO 304413 B	14/12/98
				NO 911277 A	31/05/91
				US 4938763 A,B	03/07/90
				WO 9003768 A	19/04/90
				ZA 8907511 A	26/06/91
WO	0200137	A1	03/01/02	AU 4534601 A	08/01/02
				CN 1332016 A	23/01/02
				US 6432438 B	13/08/02

INTERNATIONAL SEARCH REPORT

Information on patent family members

30/12/02

International application No.

PCT/FI 02/00979

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9639134 A1	12/12/96	AU 717260 B	23/03/00
		AU 5845796 A	24/12/96
		CA 2221784 A	12/12/96
		EP 0831808 A	01/04/98
		HU 9802573 A	28/09/99
		JP 2992677 B	20/12/99
		JP 9263545 A	07/10/97
		NO 975636 A	28/01/98
		NZ 308658 A	28/10/99
		RU 2188011 C	27/08/02
		TW 420608 B	00/00/00
		US 5910492 A	08/06/99
		BR 9602633 A	22/04/98
US 5378472 A	03/01/95	CZ 9202305 A	17/02/93
		DE 69118683 D,T	29/08/96
		EP 0512095 A,B	11/11/92
		SE 0512095 T3	
		AT 136553 T	15/04/96
		AU 639163 B	15/07/93
		AU 8956691 A	25/06/92
		CA 2074517 A	27/05/92
		CZ 281052 B	12/06/96
		ES 2084838 T	16/05/96
		HU 62017 A	29/03/93
		HU 9202434 D	00/00/00
		IT 64290 D	00/00/00
		IT 1243260 B	26/05/94
		JP 5503733 T	17/06/93
		WO 9209635 A	11/06/92

INTERNATIONAL SEARCH REPORT

Information on patent family members.

24/12/2003

International application No.

PCT/FI 2002/000979

US	5077049	A	31/12/1991	AT	100308	T	15/02/1994
				AU	653498	B	06/10/1994
				AU	6071890	A	22/02/1991
				CA	2063729	A,C	25/01/1991
				DE	69006216	D,T	05/05/1994
				DK	484387	T	14/03/1994
				EP	0484387	A,B	13/05/1992
				SE	0484387	T3	
				ES	2062540	T	16/12/1994
				FI	920293	D	00/00/0000
				HK	1005426	A	00/00/0000
				JP	2685353	B	03/12/1997
				JP	5504941	T	29/07/1993
				NO	920302	A	24/01/1992
				US	5324519	A	28/06/1994
				US	5368859	A	29/11/1994
				US	5487897	A	30/01/1996
				US	5599552	A	04/02/1997
				US	5660849	A	26/08/1997
				US	6071530	A	06/06/2000
				US	6395293	B	28/05/2002
				US	2002001608	A	03/01/2002
				WO	9101126	A	07/02/1991

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.